ZBD | $40,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Phase Genomics
United States
- Seattle, Washington
- 06/03/2024
- Unknown
- $1,500,000
Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software.
Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.
- Industry Biotechnology Research
- Website https://phasegenomics.com/
- LinkedIn https://www.linkedin.com/company/phase-genomics-inc/
Related People
Ivan Liachko 🇺🇦Co Founder
United States -
Seattle, Washington
A molecular geneticist/genomicist with over two decades of experience in wet-lab and computational biology. Founder and CEO of Seattle-based Phase Genomics Inc. (est. 2015). Passionate about applying genomic technology to improve our world and mentoring scientists interested in commercialization.
**Citations on Google Scholar*: https://scholar.google.com/citations?user=VBQJ1-gAAAAJ&hl=en
**Other Publications & News*: https://phasegenomics.com/publications/
Cubby | $63,000,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)
AnswersNow | $40,000,000 | (Jan 22, 2026)
Claim Health | $4,400,000 | (Jan 22, 2026)
Nasdaq Private Market | $37,600,000 | (Jan 22, 2026)
PraxisPro | $6,000,000 | (Jan 22, 2026)
furl | $10,000,000 | (Jan 22, 2026)